A clinical case of CADASIL syndrome

Literary information on the rather rare CADASIL syndrome is given and the actual observation of this clinical case in a patient treated in a neurological clinic is described. The course of the disease, clinical symptoms, diagnostic measures and treatment tactics are described in detail.

References

1. Yuan L., Chen X., Jankovic J., Deng H. (2024) CADASIL: A NOTCH3-associated cerebral small vessel disease. J. Adv. Res.: S2090-1232(24)00001-8.
2. Yamamoto Y., Liao Y.C., Lee Y.C. et al. (2023) Update on the Epidemiology, Pathogenesis, and Biomarkers of Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy. J. Clin. Neurol., 19(1): 12–27.
3. Tournier-Lasserve E., Joutel A., Melki J. et al. (1993) Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12. Nat. Genet., 3(3): 256–259. doi: 10.1038/ng0393-256.
4. Mizuta I., Nakao-Azuma Y., Yoshida H. et al. (2024) Progress to Clarify How NOTCH3 Mutations Lead to CADASIL, a Hereditary Cerebral Small Vessel Disease. Biomolecules, 14(1): 127. doi: 10.3390/biom14010127.
5. Ihalainen S., Soliymani R., Iivanainen E. et al. (2007) Proteome analysis of cultivated vascular smooth muscle cells from a CADASIL patient. Mol. Med., 13: 305–314.
6. Nannucci S., Pescini F., Bertaccini B. et al. (2015) Clinical, familial, and neuroimaging features of CADASIL-like patients. doi.org/10.1111/ane.12284.
7. Davous P. (1998) CADASIL: a review with proposed diagnostic criteria. Eur. J. Neurol., 5(3): 219–233. doi: 10.1046/j.1468-1331.1998.530219.x.
8. Mizuta I., Watanabe-Hosomi A., Koizumi T. et al. (2017) New diagnostic criteria for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukocencephalopathy in Japan. J. Neurol. Sci., 38: 62–67.
9. Lesnik Oberstein S.A., Jukema J.W., Van Duinen S.G. et al. (2003) Myocardial infarction in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Medicine (Baltimore), 82: 251–256.
10. Nelis P., Kleffner I., Burg M.C. et al. (2018) OCT-Angiography reveals reduced vessel density in the deep retinal plexus of CADASIL patients. Sci. Rep., 8: 8148.
11. Ragno M., Trojano L., Pianese L. et al. (2012) Renal involvement in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL): report of a case with a six-year follow-up. Histol. Histopathol., 27: 1307–1314. doi.org/10.5414/cnp67182.
12. Hack R.J., Rutten J., Lesnik Oberstein S.A.J. (2000) CADASIL [Updated 2019 Mar. 14]. In: Adam M.P., Feldman J., Mirzaa G.M. et al. (Eds.). University of Washington, Seattle, 1993–2024.
13. Tan R.Y.Y., Markus H.S. (2016) CADASIL: Migraine, Encephalopathy, Stroke and Their Inter-Relationships. PLoS One, 11: e0157613.
14. Aguilar-Fuentes V., Justo-Hernández D., Arredondo-Dubois J.M. et al. (2023) Palliative care in CADASIL: diagnosis is only the first step. Arq Neuropsiquiatr., 81(11): 1022–1024. doi: 10.1055/s-0043-1777009.
15. Charidimou A., Turc G., Oppenheim C. et al. (2017) Microbleeds, cerebral hemorrhage, and functional outcome after stroke thrombolysis: individual patient data meta-analysis. Stroke, 48: 2084–2090. doi: 10.1161/JAHA.119.012814.
16. Charidimou A., Karayiannis C., Song T.J. et al.; International META-MICROBLEEDS Initiative (2017) Brain microbleeds, anticoagulation, and hemorrhage risk: Meta-analysis in stroke patients with AF. Neurology, 89: 2317–2326.
17. Machuca-Parra A.I., Bigger-Allen A.A., Sanchez A.V. et al. (2017) Therapeutic antibody targeting of Notch3 signaling prevents mural cell loss in CADASIL. J. Exp. Med., 214(8): 2271–2282. doi: 10.1084/jem.20161715.
18. Liu X.Y., Gonzalez-Toledo M.E., Fagan A. et al. (2015) Stem cell factor and granulocyte colony-stimulating factor exhibit therapeutic effects in a mouse model of CADASIL. Neurobiol. Dis., 73: 189–203. doi: 10.1016/j.nbd.2014.09.006.